A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Study IPI-926-03 is a Phase 1b/2 clinical trial to evaluate IPI 926 in combination with
gemcitabine in patients with previously untreated metastatic pancreatic cancer. Phase 1b is
designed as a dose escalation study. Once the maximum tolerated dose of IPI-926 in
combination with gemcitabine is established in the Phase 1b portion of the study, the Phase 2
portion will commence.
Phase 2 is designed as a randomized, double-blind (investigator/patient), placebo-controlled
study. There is no cross-over option for patients in either arm of the Phase 2 (i.e., there
is no option for patients receiving placebo to cross-over to IPI-926).